Disc Medicine (IRON) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

IRON Stock Forecast


Disc Medicine stock forecast is as follows: an average price target of $66.86 (represents a 41.86% upside from IRON’s last price of $47.13) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

IRON Price Target


The average price target for Disc Medicine (IRON) is $66.86 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $89.00 to $43.00. This represents a potential 41.86% upside from IRON's last price of $47.13.

IRON Analyst Ratings


Buy

According to 13 Wall Street analysts, Disc Medicine's rating consensus is 'Buy'. The analyst rating breakdown for IRON stock is 0 'Strong Buy' (0.00%), 12 'Buy' (92.31%), 0 'Hold' (0.00%), 1 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).

Disc Medicine Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2024Roger SongJefferies$89.00$50.9274.78%88.84%
Sep 16, 2024Douglas TsaoH.C. Wainwright$70.00$47.7946.47%48.53%
Aug 22, 2024Tiago FauthWells Fargo$75.00$49.3152.10%59.13%
Aug 08, 2024Danielle BrillRaymond James$50.00$42.8516.69%6.09%
Jun 17, 2024Evan David SeigermanBMO Capital$70.00$45.8052.84%48.53%
May 10, 2024Danielle BrillRaymond James$43.00$29.9543.57%-8.76%
Apr 02, 2024Evan David SeigermanBMO Capital$50.00$34.2146.16%6.09%
Apr 01, 2024Ben BurnettStifel Nicolaus$71.00$34.21107.54%50.65%
Apr 01, 2024David NierengartenWedbush$43.00$32.0034.38%-8.76%
Apr 01, 2024Danielle BrillRaymond James$40.00$29.4036.05%-15.13%
Row per page
Go to

The latest Disc Medicine stock forecast, released on Oct 23, 2024 by Roger Song from Jefferies, set a price target of $89.00, which represents a 74.78% increase from the stock price at the time of the forecast ($50.92), and a 88.84% increase from IRON last price ($47.13).

Disc Medicine Price Target by Period


1M3M12M
# Anlaysts1410
Avg Price Target$89.00$71.00$60.10
Last Closing Price$47.13$47.13$47.13
Upside/Downside88.84%50.65%27.52%

In the current month, the average price target of Disc Medicine stock is $89.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 88.84% increase as opposed to Disc Medicine's last price of $47.13. This month's average price target is up 25.35% compared to last quarter, and up 48.09% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2024Jefferies-BuyInitialise
Oct 16, 2024Scotiabank-OutperformInitialise
Sep 16, 2024H.C. WainwrightBuyBuyHold
Aug 22, 2024Wells Fargo-OverweightInitialise
Aug 08, 2024Raymond JamesOutperformOutperformHold
Jun 14, 2024WedbushOutperformOutperformHold
Jun 13, 2024BMO CapitalOutperformOutperformHold
May 10, 2024Raymond JamesOutperformOutperformHold
Apr 02, 2024BMO CapitalOutperformOutperformHold
Apr 01, 2024WedbushOutperformOutperformHold
Row per page
Go to

Disc Medicine's last stock rating was published by Jefferies on Oct 23, 2024. The company Initialise its IRON rating from "null" to "Buy".

Disc Medicine Financial Forecast


Disc Medicine Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Disc Medicine's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IRON's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Disc Medicine EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict IRON's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Disc Medicine's previous annual EBITDA (undefined) of $NaN.

Disc Medicine Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-33.54M$-31.01M$-30.97M$-30.49M$-32.66M$-26.76M$-28.33M
High Forecast$-33.54M$-31.01M$-30.97M$-30.49M$-32.66M$-22.30M$-28.33M
Low Forecast$-33.54M$-31.01M$-30.97M$-30.49M$-32.66M$-30.66M$-28.33M
Surprise %-------

Disc Medicine's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IRON's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Disc Medicine SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Disc Medicine's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IRON last annual SG&A of $NaN (undefined).

Disc Medicine EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-1.31$-1.21$-1.21$-1.19$-1.27$-1.04$-1.10
High Forecast$-1.31$-1.21$-1.21$-1.19$-1.27$-0.87$-1.10
Low Forecast$-1.31$-1.21$-1.21$-1.19$-1.27$-1.20$-1.10
Surprise %-------

According to undefined Wall Street analysts, Disc Medicine's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IRON previous annual EPS of $NaN (undefined).

Disc Medicine Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
FENCFennec Pharmaceuticals$4.34$15.75262.90%Buy
ANEBAnebulo Pharmaceuticals$1.84$6.00226.09%Buy
ACRVAcrivon Therapeutics$8.01$22.00174.66%Buy
DAWNDay One Biopharmaceuticals$14.65$38.80164.85%Buy
LRMRLarimar Therapeutics$7.74$20.33162.66%Buy
BMEABiomea Fusion$9.04$22.75151.66%Buy
ABOSAcumen Pharmaceuticals$2.85$7.00145.61%Buy
OLMAOlema Pharmaceuticals$11.62$28.50145.27%Buy
ANABAnaptysBio$21.68$52.33141.37%Buy
GPCRStructure Therapeutics$41.14$92.40124.60%Buy
MLYSMineralys Therapeutics$13.45$30.00123.05%Buy
TERNTerns Pharmaceuticals$6.94$14.25105.33%Buy
MLTXMoonLake Immunotherapeutics$46.76$79.3369.65%Buy
ADAGAdagene$3.00$5.0066.67%Buy
IRONDisc Medicine$47.13$66.8641.86%Buy
CNTACentessa Pharmaceuticals$15.67$21.6738.29%Buy
DICEDICE Therapeutics$47.55$60.0026.18%Buy
CRNXCrinetics Pharmaceuticals$56.69$70.1423.73%Buy
TRDAEntrada Therapeutics$17.60$18.002.27%Buy
MORFMorphic$56.99$57.000.02%Hold
AMLXAmylyx Pharmaceuticals$5.64$5.33-5.50%Buy

IRON Forecast FAQ


Yes, according to 13 Wall Street analysts, Disc Medicine (IRON) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 92.31% of IRON's total ratings.

Disc Medicine (IRON) average price target is $66.86 with a range of $43 to $89, implying a 41.86% from its last price of $47.13. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for IRON stock, the company can go up by 41.86% (from the last price of $47.13 to the average price target of $66.86), up by 88.84% based on the highest stock price target, and down by -8.76% based on the lowest stock price target.

IRON's highest twelve months analyst stock price target of $89 supports the claim that Disc Medicine can reach $70 in the near future.

1 Wall Street analyst forecast a $89 price target for Disc Medicine (IRON) this month, up 88.84% from its last price of $47.13. Compared to the last 3 and 12 months, the average price target increased by 50.65% and increased by 27.52%, respectively.

Disc Medicine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-87.74M (high $-83.281M, low $-91.641M), average SG&A $0 (high $0, low $0), and average EPS is $-3.421 (high $-3.247, low $-3.573). IRON's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-126M (high $-126M, low $-126M), average SG&A $0 (high $0, low $0), and average EPS is $-4.913 (high $-4.913, low $-4.913).